Home | Welcome to Contract Pharma   
Last Updated Wednesday, June 3 2015

Print

Search Results for 'Phase II'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Contract Service Directory Companies

View All Companies »


Contract Service Directory Categories

View All Categories »


Search Results:

Published June 2, 2015
Will evaluate investigational candidates in cancer patients Read More »
By Tim Wright, Editor
Published June 2, 2015
PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market Read More »
Applying Risk-Based Monitoring in the Real World
By Lynn King, TKL Research
Published June 2, 2015
Implementing an acceptable clinical monitoring plan requires a thorough understanding of the new rules under which we’re operating Read More »
Challenges in Global Biosimilar Development: A Regulatory Perspective
By Patricia Hurley, Joan Boren and Costantino Congiatu, PPD
Published June 2, 2015
More than $60 billion worth of patents on biological products are expiring before 2020, representing a major opportunity for the pharmaceutical industry. Read More »
Published June 1, 2015
Will focus on exploring potential combinations of PS-targeting agents Read More »
Published May 20, 2015
Will use Achillion assets to develop pan-genotypic oral regimen for HCV Read More »
Published May 12, 2015
Secures exclusive option to acquire the company following a Phase II trial of recAP Read More »
Published May 11, 2015
The new facility has already been deployed to manufacture a Humira biosimilar candidate in an upcoming Phase III trial Read More »
Published May 6, 2015
Hare brings 28 years of experience in the biopharma and CROs industries Read More »
Published May 6, 2015
Opens new 36,000-sq.-ft., 160-bed clinical research center in Secaucus Read More »
Published May 5, 2015
Will assume clinical development and commercialization of ISIS-FXIRx Read More »
Published May 5, 2015
Industry veteran Treiber to lead clinical development across a wide range of therapeutic areas Read More »
Published May 5, 2015
To add commercial spray-drying capacity for inhalation technologies to treat
a wider range of diseases Read More »
Published April 23, 2015
Initiates Phase III Trial Read More »
Published April 16, 2015
Will conduct combination trails in melanoma Read More »
Published April 14, 2015
Completes production of a commercial scale lot of EVK-001 in accordance with CMC Read More »
Published April 13, 2015
Diversifies development risk with second, complementary acute pain product Read More »
Published April 13, 2015
New website has been launched at www.juniperpharma.com Read More »
Published April 8, 2015
Drs. Rozenman and Holfinger to oversee Phase III trial of lead product, AR 101 Read More »
Published April 6, 2015
Will evaluate Alimta and carboplatin with Demcizumab in NSCLC Read More »
Published April 2, 2015
Change over will become official on April 13 Read More »
Published April 1, 2015
Granted authorization to produce lentiviral vectors for clinical use and CAR-T cell therapies Read More »
Published March 30, 2015
Expands CNS franchise Read More »
Published March 26, 2015
Fully operational to supply comprehensive immunotherapeutic treatments Read More »
Published March 23, 2015
Introduces new corporate identity and logo Read More »
Published March 19, 2015
Will perform tech transfer and support clinical trial for ICT-107 Read More »
Published March 19, 2015
Phase II study will evaluate the safety and pharmacokinetics of Translarna in MPS I Read More »
Published March 19, 2015
To develop and commercialize Hanmi's oral BTK inhibitor Read More »
Published March 16, 2015
To discover and develop anti-cancer immunotherapies Read More »
Published March 12, 2015
Kura responsible for development and commercialization Read More »
Published March 6, 2015
Advances Phase III Evaluation of SMNRx Read More »
By Brigitte de Lima, Results Healthcare
Published March 6, 2015
A huge opportunity for savvy service providers Read More »
Reporting Transparency
By Yvonne Moores , Executive Vice President, Operations, Quanticate Ltd.
Published March 6, 2015
How to work with a CRO to get patient safety narratives right the first time Read More »
Consolidation in Outsourcing
By Michael A. Martorelli , Director, Fairmount Partners
Published March 6, 2015
Reviewing 2014’s M&A activity Read More »
Published March 4, 2015
Gains exclusive option to license the Phase III prostate cancer immunotherapy Read More »
Published March 2, 2015
Advances Phase II/III study of ISIS-TTR in FAP Read More »
Published February 25, 2015
Opens newly expanded office Read More »
Published February 24, 2015
Gains Phase III drug for gastrointestinal disease Read More »
Published February 23, 2015
Merck to purchase 15% equity stake in NGM Read More »
Published February 20, 2015
AMPLEX and PREFIX are ready for Phase III Read More »
Published February 19, 2015
Will use LymPro test to evaluate lead drug candidate combination Read More »
Published February 4, 2015
Phase II trial shows progression-free survival in beast cancer Read More »
Published February 2, 2015
Mylan to manufacture TD-4208 and will lead commercialization in the U.S. Read More »
Jump Starting the Non-Profit Research Engine
By Kate Hilyard , Managing Director, BioFocus
Published January 29, 2015
How CROs are teaming up with disease foundations to accelerate drug discovery. Read More »
Supplier Selection: A Roadmap to a Good Start
By George Tyson, CMC and supply chain consultant
Published January 29, 2015
Good supplier selection is a key element of success in the pharmaceutical industry today. Read More »
Published January 20, 2015
Aims to improve asset development and delivery timelines Read More »
Published January 16, 2015
Gains Funding from Innovative Medicines Initiative Read More »
Published January 14, 2015
Gains exclusive rights to Phase III immuno-oncology compound Read More »
Published January 13, 2015
To evaluate pembrolizumab in combination with Lilly compounds Read More »
Published January 12, 2015
Gains portfolio of candidates for neuropathic pain Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On